First Trust Advisors
ALDX icon

First Trust Advisors’s Aldeyra Therapeutics ALDX Stock Holding History

First Trust Advisors’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-146,320
Closed -$1.66M – 2508
2021
Q2 		$1.66M Buy
146,320
+26,205
+22% +$315K ﹤0.01% 1877
2021
Q1 		$1.43M Buy
120,115
+26,195
+28% +$302K ﹤0.01% 1853
2020
Q4 		$644K Sell
93,920
-3,772
-4% -$26.5K ﹤0.01% 2050
2020
Q3 		$724K Buy
+97,692
New +$631K ﹤0.01% 1898

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM

First Trust Advisors's ALDX Position: Q3 2021 in Review

First Trust Advisors sold out of Aldeyra Therapeutics (ALDX) in Q3 2021, closing a stake of 146,320 shares — an estimated $1.66M sold.

First Trust Advisors first reported a position in ALDX in Q3 2020 and held it in 4 quarters. The position peaked at $1.66M in Q2 2021. 117 funds tracked by Wall St. Rank hold ALDX as of Q3 2021.

  • First Trust Advisors reported no remaining Aldeyra Therapeutics position as of Q3 2021 after selling out during the quarter.
  • First Trust Advisors sold 146,320 Aldeyra Therapeutics shares in Q3 2021, an estimated $1.66M.
  • First Trust Advisors first reported a position in Aldeyra Therapeutics in Q3 2020 and held it in 4 quarters.
  • First Trust Advisors's Aldeyra Therapeutics position peaked at $1.66M in Q2 2021.
  • 117 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2021.

Based on First Trust Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.